During the past decade, Institut d'Hématologie et d'Oncologie Pédiatrique conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut d'Hématologie et d'Oncologie Pédiatrique" #1 sponsor was "Centre Leon Berard" with 6 trials, followed by "Centre Hospitalier Universitaire de Saint Etienne" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "ADDMEDICA SASA" with 1 trials sponsored and "ANRS, Emerging Infectious Diseases" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut d'Hématologie et d'Oncologie Pédiatrique" #1 collaborator was "ClinSearch" with 1 trials as a collaborator, "European Society for Blood and Marrow Transplantation" with 1 trials as a collaborator, "Institut d'Hématologie et d'Oncologie Pédiatrique" with 1 trials as a collaborator, "Ligue contre le cancer, France" with 1 trials as a collaborator and "National Cancer Institute, France" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Institut d'Hématologie et d'Oncologie Pédiatrique" are "Acute Leukemia" (3 trials), "Cancer" (3 trials), "Acute Lymphoblastic Leukemia" (2 trials), "Bone Marrow Aplasia" (2 trials) and "Complications" (2 trials). Many other conditions were trialed in "Institut d'Hématologie et d'Oncologie Pédiatrique" in a lesser frequency.

Most popular intervention types in "Institut d'Hématologie et d'Oncologie Pédiatrique" are "Drug" (8 trials), "Other" (8 trials), "Biological" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Physical activity program" (2 trials), "Alectinib" (1 trials), "Atezolizumab" (1 trials), "Autonomic nervous system activity records" (1 trials) and "Brexucabtagene Autoleucel (KTE-X19)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut d'Hématologie et d'Oncologie Pédiatrique" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Institut d'Hématologie et d'Oncologie Pédiatrique". 1 are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Institut d'Hématologie et d'Oncologie Pédiatrique, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institut d'Hématologie et d'Oncologie Pédiatrique, 4 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".

Institut d'Hématologie et d'Oncologie Pédiatrique has several departments that took part in Clinical trials: "Institute for Pediatric Hematology - Oncology, Leon Berard Cancer Center" - 3 trials